Clinical OMICS

MAR-APR 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 5 of 51

4 Clinical OMICs March/April 2018 News because they are the only ones that are able to break down the data silos." In addition to launching the plat- form, Seqster has begun partnering with the Boston University Ryan Cen- ter focused on enrolling participants in a traumatic brain injury (TBI) study, as well as tracking and monitoring their personal health data. Like, Seqster is free to consumer users. Asked how Seqster will generate revenue, Arianpour replied: "Our primary focus right now is building relationships with organi- zations like Boston University to get people to join Seqster. What is import- ant now is supporting consumers to help them aggregate all of their health data and put it in a common form to help them, their families, and society. Revenue sources will be many and flow directly to Seqster users." Seqster reasons that by forging partnerships across the healthcare spectrum, it can best roll out its direct-to-consumer platform later this year. The company envisions early applications of its technology that include disease-specific community engagement, acute and chronic care navigation for individuals and fam- ily members—and as with the Boston University partnership, clinical trial enrollment support. The Boston University Ryan Cen- ter 's proof-of-concept study aims to identify potential digital biomarkers of traumatic brain injury in concussed patients and potentially improve clin- ical diagnosis and treatment of head injury. The study will consist of acute TBI (concussed patients) and non- TBI subjects who participate in con- tact sports and are currently seeking medical attention at the Ryan Center for either brain injuries or injuries not related to the brain, Seqster and the Ryan Center said. Researchers from the Ryan Cen- ter will use the platform's Seqster Research Portal, which allows aca- demic or pharmaceutical users that conduct clinical trials to rapidly enroll participants into the study, then aggre- gate all available health data directly from the source. Seqster took two years to develop, during which Arianpour 's grand- mother died of Alzheimer 's disease a year ago. "It occurred to me that not only was she not able to pass her health data onto me, my brother, and my mom, but she was unable to pass it onto society. Every moment, people pass away without passing on their health data. Now with Seqster, we've created something to be able to pre- serve it and pass it on." Seqster has raised more than $4 mil- lion in seed financing, and is now pur- suing a Series A financing intended to support a broader launch of the plat- form for consumers. Arianpour would not disclose how much Series A capital the company plans to raise, except to say it would be significantly higher. Arianpour is one of four Seqster executives. The others are CTO and co-founder Xiang (Sean) Li,, Ph.D.; CIO and Co-Founder, Dana Hosseini; and Strategic Advisor Matt Patterson, M.D. The Seqster portal will put each person's health and genomic data at their fingertips. pandpstock001 / Getty Images (continued from previous page)

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2018